ArticleBMC cancer2022

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.

Sanne Ten Hoorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.